Enhanced expression of nuclear factor I/B in oxaliplatin-resistant human cancer cell lines

Cancer Science

Volumn 102, Issue 2, 2011, Pages 382-386

  Kashiwagi, Eiji ^a,b   Izumi, Hiroto ^a   Yasuniwa, Yoshihiro ^a   Baba, Ryoko ^a   Doi, Yoshiaki ^a   Kidani, Akihiko ^a   Arao, Tokuzo ^c   Nishio, Kazuto ^c   Naito, Seiji ^b   Kohno, Kimitoshi ^a  

^a UNIVERSITY OF OCCUPATIONAL AND ENVIRONMENTAL HEALTH   (Japan)

^b KYUSHU UNIVERSITY   (Japan)

^c KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; NUCLEAR FACTOR IB; OXALIPLATIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

ARTICLE; BLADDER CANCER; CANCER CELL; CANCER CELL CULTURE; COLON CANCER; CONTROLLED STUDY; CROSS RESISTANCE; DOWN REGULATION; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; UPREGULATION;

ANTINEOPLASTIC AGENTS; BLOTTING, WESTERN; CELL LINE, TUMOR; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; NEOPLASMS; NFI TRANSCRIPTION FACTORS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORGANOPLATINUM COMPOUNDS; TUMOR MARKERS, BIOLOGICAL;

EID: 79952083052     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01784.x     Document Type: Article

References (33)

1. Ohga T, Koike K, Ono M et al. Role of the human Y box-binding protein YB-1 in cellular sensitivity to the DNA-damaging agents cisplatin, mitomycin C, and ultraviolet light. Cancer Res 1996; 56: 4224-8.
2. Kohno K, Uchiumi T, Niina I et al. Transcription factors and drug resistance. Eur J Cancer 2005; 41: 2577-86.
3. Torigoe T, Izumi H, Ishiguchi H et al. Cisplatin resistance and transcription factors. Curr Med Chem Anticancer Agents 2005; 5: 15-27.
4. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-65.
5. Pendyala L, Creaven PJ. In vitro cytotoxicity, protein binding, red blood cell partitioning, and biotransformation of oxaliplatin. Cancer Res 1993; 53: 5970-6.
6. Raymond E, Faivre S, Chaney S, Woynarowski J, Cvitkovic E. Cellular and molecular pharmacology of oxaliplatin. Mol Cancer Ther 2002; 1: 227-35.
7. Mishima M, Samimi G, Kondo A, Lin X, Howell SB. The cellular pharmacology of oxaliplatin resistance. Eur J Cancer 2002; 38: 1405-12.
8. McKeage MJ. New-generation platinum drugs in the treatment of cisplatin-resistant cancers. Expert Opin Investig Drugs 2005; 14: 1033-46.
9. Noordhuis P, Laan AC, van de Born K, Losekoot N, Kathmann I, Peters GJ. Oxaliplatin activity in selected and unselected human ovarian and colorectal cancer cell lines. Biochem Pharmacol 2008; 76: 53-61.
10. Chollet P, Bensmaïne MA, Brienza S et al. Single agent activity of oxaliplatin in heavily pretreated advanced epithelial ovarian cancer. Ann Oncol 1996; 7: 1065-70.
11. Rabik CA, Dolan ME. Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 2007; 33: 9-23.
12. Martinez-Balibrea E, Plasencia C, Ginés A et al. A proteomic approach links decreased pyruvate kinase M2 expression to oxaliplatin resistance in patients with colorectal cancer and in human cell lines. Mol Cancer Ther 2009; 8: 771-8.
13. Samimi G, Manorek G, Castel R et al. cDNA microarray-based identification of genes and pathways associated with oxaliplatin resistance. Cancer Chemother Pharmacol 2005; 55: 1-11.
14. Hector S, Nava ME, Clark K, Murphy M, Pendyala L. Characterization of a clonal isolate of an oxaliplatin resistant ovarian carcinoma cell line A2780/C10. Cancer Lett 2007; 245: 195-204.
15. Yang J, Parsons J, Nicolay NH et al. Cells deficient in the base excision repair protein, DNA polymerase beta, are hypersensitive to oxaliplatin chemotherapy. Oncogene 2010; 29: 463-8.
16. Varma RR, Hector SM, Clark K, Greco WR, Hawthorn L, Pendyala L. Gene expression profiling of a clonal isolate of oxaliplatin-resistant ovarian carcinoma cell line A2780/C10. Oncol Rep 2005; 14: 925-32.
17. Plasencia C, Martínez-Balibrea E, Martinez-Cardús A, Quinn DI, Abad A, Neamati N. Expression analysis of genes involved in oxaliplatin response and development of oxaliplatin-resistant HT29 colon cancer cells. Int J Oncol 2006; 29: 225-35.
18. Benedetti V, Perego P, Luca Beretta G et al. Modulation of survival pathways in ovarian carcinoma cell lines resistant to platinum compounds. Mol Cancer Ther 2008; 7: 679-87.
19. Ekblad L, Kjellström J, Johnsson A. Reduced drug accumulation is more important in acquired resistance against oxaliplatin than against cisplatin in isogenic colon cancer cells. Anticancer Drugs 2010; 21: 523-31.
20. Martelli L, Ragazzi E, Di Mario F, Basato M, Martelli M. Cisplatin and oxaliplatin cytotoxic effects in sensitive and cisplatin-resistant human cervical tumor cells: time and mode of application dependency. Anticancer Res 2009; 29: 3931-7.
21. Igarashi T, Izumi H, Uchiumi T et al. Clock and ATF4 transcription system regulates drug resistance in human cancer cell lines. Oncogene 2007; 26: 4749-60.
22. Tanabe M, Izumi H, Ise T et al. Activating transcription factor 4 increases the cisplatin resistance of human cancer cell lines. Cancer Res 2003; 63: 8592-5.
23. Shiota M, Izumi H, Onitsuka T et al. Twist promotes tumor cell growth through YB-1 expression. Cancer Res 2008; 68: 98-105.
24. Miyamoto N, Izumi H, Noguchi T et al. Tip60 is regulated by circadian transcription factor clock and is involved in cisplatin resistance. J Biol Chem 2008; 283: 18218-26.
25. Wakasugi T, Izumi H, Uchiumi T et al. ZNF143 interacts with p73 and is involved in cisplatin resistance through the transcriptional regulation of DNA repair genes. Oncogene 2007; 26: 5194-203.
26. Grothey A, Sargent D, Goldberg RM, Schmoll HJ. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment. J Clin Oncol 2004; 22: 1209-14.
27. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol 2006; 17: 1818-25.
28. Reed E. Nucleotide excision repair and anti-cancer chemotherapy. Cytotechnology 1998; 27: 187-201.
29. Gronostajski RM. Site-specific DNA binding of nuclear factor I: effect of the spacer region. Nucleic Acids Res 1987; 15: 5545-59.
30. Ise T, Nagatani G, Imamura T et al. Transcription factor Y-box binding protein 1 binds preferentially to cisplatin-modified DNA and interacts with proliferating cell nuclear antigen. Cancer Res 1999; 59: 342-6.
31. Todd RC, Lippard SJ. Inhibition of transcription by platinum antitumor compounds. Metallomics 2009; 1: 280-91.
32. Uramoto H, Izumi H, Nagatani G et al. Physical interaction of tumour suppressor p53/p73 with CCAAT-binding transcription factor 2 (CTF2) and differential regulation of human high-mobility group 1 (HMG1) gene expression. Biochem J 2003; 371: 301-10.
33. Sharma S, Gong P, Temple B, Bhattacharyya D, Dokholyan NV, Chaney SG. Molecular dynamic simulations of cisplatin- and oxaliplatin-d(GG) intrastand cross-links reveal differences in their conformational dynamics. J Mol Biol 2007; 373: 1123-40.